National Drug Strategy
National Drug Strategy

National Drug Strategy 2010-2015 Roundtable Consultation Report

9 Performance measures

prev pageTOC |next page

The participants at each roundtable consultation were asked to consider and discuss the following questions:

There was a broad discussion about having discrete performance measures tied to the NDS. While many participants thought that without having performance measures tied to the NDS, its value was diminished, others felt this to be difficult as it provides a broad policy framework for guidance to jurisdictions. Others noted the complexity in getting agreement on a set of measures and then having the jurisdictions agree to collect the data. For example it was noted that despite national agreement on the collection of alcohol sales data the liquor licence fee data is only collected in three states. From a law enforcement perspective it was noted that there is difficulty in measuring performance, especially in relation to measuring harm, as figures are often activity based.

A suggestion was made that rather than focussing on performance measures consideration be given to looking at a core set of indicators, which provide guidance on progress. These measures include population indicators such as smoking rates or a delay in the age of cannabis uptake. Alternatively indicators may be focused on the achievement of outcomes for example, death, crime, disease, economic costs and impacts.

prev pageTOC |next page